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Facioscapulohumeral muscular dystrophy (FSHD)
is an enigmatic disease associated with epigenetic
alterations in the subtelomeric heterochromatin of
the D4Z4 macrosatellite repeat. Each repeat unit en-
codes DUX4, a gene that is normally silent in most
tissues. Besides muscular loss, most patients suffer
retinal vascular telangiectasias. To generate an ani-
mal model, we introduced a doxycycline-inducible
transgene encoding DUX4 and 30 genomic DNA into
a euchromatic region of the mouse X chromosome.
Without induction, DUX4 RNA was expressed at
low levels in many tissues and animals displayed a
variety of unexpected dominant leaky phenotypes,
including male-specific lethality. Remarkably, rare
live-born males expressed DUX4 RNA in the retina
and presented a retinal vascular telangiectasia. By
using doxycycline to induce DUX4 expression in sat-
ellite cells, we observed impairedmyogenesis in vitro
and in vivo. This mouse model, which shows pathol-
ogies due to FSHD-related D4Z4 sequences, is likely
to be useful for testing anti-DUX4 therapies in FSHD.
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is a common
degenerative myopathy caused by illicit recombination within
D4Z4, a subtelomeric macrosatellite repeat on chromosome 4
(van Deutekom et al., 1993; Wijmenga et al., 1992). Array con-
tractions cause chromatin changes (de Greef et al., 2009; Gabel-
lini et al., 2002; van Overveld et al., 2003; Zeng et al., 2009) but
cause disease only on a specific allele of chromosome 4, termed
4qA161 (Lemmers et al., 2004, 2007). FSHD nonpermissive1484 Cell Reports 8, 1484–1496, September 11, 2014 ª2014 The Aualleles, and related D4Z4 repeats on chromosome 10 (Bakker
et al., 1995; Deidda et al., 1996), lack an ATTAAA polyadenyla-
tion sequence downstream of the terminal repeat (Dixit et al.,
2007; Lemmers et al., 2010). These data suggest that repeat
contractions result in an mRNA transcript produced from
D4Z4, which must be polyadenylated to cause disease.
The D4Z4 transcript bears an open reading frame encoding
a double homeodomain protein named DUX4 (Gabrie¨ls et al.,
1999), and this protein is specifically expressed, albeit ex-
tremely weakly, in FSHD (Dixit et al., 2007; Snider et al.,
2010). Expression of DUX4 at very low levels interferes with
myogenesis and sensitizes cells to oxidative stress (Bosnakov-
ski et al., 2008a). These low-level effects are intriguing as
defects in myogenic gene expression (Celegato et al., 2006; Wi-
nokur et al., 2003a) and sensitivity to oxidative stress (Turki
et al., 2012; Winokur et al., 2003b) have been detected in
FSHD muscle and primary cell cultures. High levels of DUX4
expression cause rapid cell death in vitro (Bosnakovski et al.,
2008a; Kowaljow et al., 2007).
In addition to muscle wasting, most individuals afflicted with
FSHD have subclinical retinal vascular pathologies involving
vascular tortuosity, microaneurysms, occlusions, and occasion-
ally small exudates (Fitzsimons et al., 1987; Padberg et al., 1995).
A transgenic mouse has recently been described that carries
an insertion of tandem arrays of a 2.5-unit FSHD allele. Although
transcription could be detected in several tissues, and very rare
DUX4+ nuclei were detected in cultured cells from this animal
(Krom et al., 2013), the animal was normal except for an eye
keratitis that developed with age. With the aim of studying the
effect of DUX4 expression in vivo, we generated mice with a
doxycycline (dox)-inducible DUX4 transgene upstream of hypo-
xanthine phosphor-ribosyl transferase (HPRT) on the X chromo-
some. Unexpectedly, in the absence of dox, these animals
display a variety of pathologies. We characterize these pathol-
ogies and use this model to investigate effects of D4Z4/DUX4
expression on myogenic progenitor cell activity.thors
RESULTS
To generate a dox-inducible, DUX4-expressing mouse, we used
inducible cassette exchange recombination (Bosnakovski et al.,
2008a; Iacovino et al., 2011) to insert a genomic DNA fragment
encoding the DUX4 open reading frame and 30 sequences
from the terminal D4Z4 repeat up to the EcoRI site into a eu-
chromatic site on the X chromosome. This site, upstream of a
functional HPRT gene, was chosen for its ability to give reliable
transgene expression (Bronson et al., 1996; Cvetkovic et al.,
2000; Portales-Casamar et al., 2010; Touw et al., 2007). The inte-
gration places this genomic DNA into a dox-inducible locus
regulated by a second generation, tight, tet-response element
(Agha-Mohammadi et al., 2004). The reverse tetracycline trans-
activator for the Tet-On system is expressed ubiquitously from
Rosa26 (Hochedlinger et al., 2005). The integration vector pro-
vides an SV40 poly A signal downstream of the inserted DNA.
We named this transgene iDUX4(2.7), because DUX4 is on a
2.7 kb genomic fragment (Figure 1A).
The iDUX4(2.7) Transgene Is Male-Specific
Dominant Lethal
Blastocyst injection generated chimeric males with poor trans-
mission of the transgene: only two F1 progeny were obtained af-
ter 1 year of mating chimeras to C57BL/6 females. These carrier
females displayed a striped mosaic scaly skin, mild alopecia
phenotype. They transmitted the transgene to female progeny,
but most litters lacked male carriers (Figure 1B), demonstrating
that the DUX4(2.7) transgene behaved as a male-specific domi-
nant embryonic lethal. Evaluation of embryonic litters at embry-
onic day 14.5 (E14.5) revealed male carrier fetuses with various
degrees of developmental delay (Figure 1C). Rarely, carrier
males survived to birth, and these animals were runted, dis-
played the skin phenotype homogeneously, and invariably died
before 2 months of age. Notably, when carrier males survived
to term, they were usually of similar size to littermate controls
at birth. The runting and the skin phenotypes usually became
apparent within a few days but were sometimes not initiated until
the second week (Figure 1D), and by 6 weeks, iDUX4(2.7) males
were significantly underweight (Figure 1E). On histological exam-
ination, the skin was found to have excessive numbers of cells, in
both the epidermis and dermis (Figures 1F and 1G), features that
may explain the flaky scaly skin, and alopecia. We evaluated
various tissues from affected males for leaky expression of the
transgene (Figure 1H). Unexpectedly, expression in skin, as in
most other tissues, was very low and inconsistently detected
at 38 cycles of RT-PCR. Nor did we detect the DUX4 protein in
any tissues in the absence of dox. This situation is very reminis-
cent of patients with FSHD, in which spliced RNA transcripts
from the terminal D4Z4 element can be detected by RT-PCR in
most samples but protein is exceedingly difficult to detect.
However, DUX4 mRNA was consistently detected in testis,
retina, and brain. DUX4 has been detected in normal human
testis (Snider et al., 2010), and FSHD patients present retinal
vascular defects; therefore, we evaluated these tissues in
greater detail. Compared to sibling controls, testes of 42-day-
old iDUX4(2.7) males displayed a marked defect in gameto-
genesis. Seminiferous tubule cross sections showed almostCell Recomplete loss of spermatocytes during late prophase in most
tubules. This resulted in relatively few tubules that contained
round haploid spermatids and a lack of elongating spermatids
compared to wild-type (WT) siblings (Figures 2A and 2B).
To evaluate retinae, we generated montages of z stack laser-
scanning confocal microscopy images of retinal whole mounts
stained with PECAM antibody. The iDUX4(2.7) males displayed
features associated with telangiectasia: excessive branching
with looping and twisted retinal vessels, which appear more
dilated than control retinae (Figures 2C and 2D). Morphometric
analysis of these images revealed a dramatic increase in vessel
branching (nodes), as well as significant increases in vessel
length and overall density of vessels in iDUX4(2.7) males
compared to controls (Figures 2E–2G), suggestive of increased
neovascularization.
iDUX4(2.7) Males Have Proportionally Weaker Muscles
but Show No Evidence of Muscular Dystrophy prior to
6 Weeks of Age
Muscles of the iDUX4(2.7) males were smaller than those of their
matched sibling controls and fibers were fewer and smaller;
however, muscles did not become overtly dystrophic within
the short lifespan of these mice (Figure 3A). Grip-strength mea-
surements revealed that the iDUX4(2.7) males were much
weaker than sibling controls, but strength was proportional to
body size (Figure 3B). We measured the force-generation ca-
pacity of isolated extensor digitorum longus (EDL) and soleus
muscles. Both muscles produced much lower absolute force;
however, when normalized to muscle cross-sectional area, the
specific force-generating capacity was not significantly different
from WT (Figures 3C and 3D). Soleus muscle fiber type distribu-
tion, based on myosin heavy chain isoform expression (types 1,
2a, and 2x), was not different between iDUX4(2.7) and wild-type
mice (Figure 3E).
Demethylation of DUX4 in Myogenic and FAP
Progenitors from Muscle
To determine whether the integrated transgene more resembled
an FSHD-associated or a WT allele, we evaluated methylation of
the transgene in rare live-born iDUX4(2.7) males by bisulfite
sequencing. We initially evaluated testis and hind limb muscle,
tissues with visualizable versus barely detectable DUX4 mRNA.
Remarkably, in both tissues, the transgene was completely de-
methylated (Figure 4A). We then initiated cultures of total muscle
mononuclear cells and subsequently fluorescence-activated cell
sorting (FACS) purified and subcultured the a7-integrin
PDGFRa+ fibroadipogenic (FAP) (Joe et al., 2010; Uezumi
et al., 2010) and the a7-integrin+ PDGFRa myoblast fractions.
The transgene was likewise completely demethylated in both
progenitor cell types (Figures 4A and S1).
Biased X Inactivation in Females
We then investigated methylation in females, using peripheral
blood samples of female iDUX4(2.7) heterozygous breeders.
In stark contrast to males, sequences from females indi-
cated that the gene could be in one of two states: either
similar to that seen in males or heavily methylated. This is
consistent with X inactivation, which, when it occurred on theports 8, 1484–1496, September 11, 2014 ª2014 The Authors 1485
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Figure 2. Phenotypes in Testis and Retina
(A) Cross section through WT seminiferous tu-
bules. The scale bar represents 50 mm.
(B) Cross section through iDUX4(2.7) seminiferous
tubules.
(C) Vasculature in WT retina: montage of z stack
laser scanning confocal microscopy images of
retina flat mounts stained with anti-CD31/PECAM
showing normal presentation of vasculature. The
scale bar represents 50 mm.
(D) Vasculature in iDUX4(2.7) retina showing dense
network of disorganized and twisted/looping ves-
sels. Yellow arrows indicate twisted vessels.
(E) Morphometric analysis of retinal images
following skeletonization showing vascular density
measured as immunoreactive pixels (p < 0.05).
(F) Morphometric quantification of vessel branch-
ing measured by nodes (p < 0.001).
(G) Morphometric quantification of total vessel
length. For (E)–(G), each point represents values/
field, averaged from three to four different fields
per retina; n = 7 iDUX4, n = 8 WT (p < 0.01).DUX4-bearing X, would result in high levels of methylation.
Because X inactivation is random, an equal proportion of the
two states is expected. Remarkably, the methylated sequences
greatly outnumbered the demethylated sequences in females
(Figure 4B). This X inactivation bias strongly suggests that there
is selection against cells that inactivate the WT X, leading fe-Figure 1. The iDUX4(2.7) Transgene Is Male-Specific Dominant Lethal
(A) Schematics of the terminal D4Z4 repeat (above), the DUX4 transcript with introns and proposed AATAAA
integrated into the X chromosome (bottom). HPRT, hypoxanthine phosphor-ribosyl transferase; Ex1, exon 1
(B) Genotypes of live pups from iDUX4(2.7) female carriers bred to WT males and chi-square p values.
(C) iDUX(2.7) embryos at E14.5. XD4 indicates the transgenic iDUX4(2.7)-bearing chromosome. Most mal
resorption.
(D) Examples of litters with runted iDUX4(2.7) males. Left: a P5 litter with two obvious runts and one animal, id
became runted. Right: littermate WT and iDUX4(2.7) males at P28.
(E) Weight at 6 weeks, p < 0.05.
(F) H&E staining of skin. Note the hypertrophic epithelium (filled arrowhead) and the abnormal glands (open
(G) The epidermal thickness and nuclear density in the dermis were measured at six locations per sectio
experiment was repeated with three mice.
(H) RT-PCR detection of the DUX4 transcript in tissues of iDUX4(2.7) transgenic male mice. Robust and rep
retina, and testis. Other tissues displayed sporadic and weaker expression.
Cell Reports 8, 1484–1496, Sepmale heterozygotes to be composed
mainly of cells in which the DUX4-
bearing X was inactivated.
Expression of DUX4 in Muscle-
Derived Progenitors
In contrast to the difficulty of detecting
DUX4 transcript in primary muscle tissue,
the DUX4 transcript was detectable at
low levels in both myoblasts and FAPs
(Figure 4C). Notably, in iDUX4(2.7) cul-
tures, the FAP population predominated
prior to FACS and isolated iDUX4(2.7)
myoblasts had a clear growth disadvan-
tage compared to their WT controls,
whereas iDUX4(2.7) FAPs showed no
growth disadvantage (Figure 4D). We next sought to detect
the DUX4 protein in isolated myoblasts and FAPs. We found
no detectable protein expression in FAPs (not shown); however,
myoblast cultures consistently showed scattered cells with nu-
clear DUX4 protein (Figure 4E), similar to what was seen with
the D4Z4 mouse (Krom et al., 2013). The protein could also bepolyadenylation signal (below), and the construct
; sgTRE, second-generation tet-response element.
e carrier embryos display severe growth delay or
entified by arrowhead, with some hair loss that later
arrowhead). The scale bar represents 20 mm.
n and averaged (*p < 0.04; **p < 0.001), and the
eatable expressions were always seen in the brain,
tember 11, 2014 ª2014 The Authors 1487
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Figure 3. Muscle in iDUX4(2.7) Animals
(A) H&E staining of cross sections through soleus muscles of iDUX4(2.7) males (left) and male littermate controls (right). The scale bar represents 100 mm (low-
magnification images) or 200 mm (high-magnification images).
(B) Grip strength measurements at 6 weeks: absolute at left (p < 0.001) and normalized to body mass at right (n = 4).
(C) Maximal isometric force generated by the extensor digitorum longus muscle at 6 weeks: absolute at left (p < 0.001) and normalized to cross-sectional area at
right (n = 4).
(D) Maximal isometric force generated by the soleus muscle at 6 weeks: absolute at left (p = 0.026) and normalized to cross-sectional area at right (n = 4).
(E) Fiber-type analysis based on myosin heavy chain isoform expression.detected, and at greater frequency, in nuclei from differentiated
myotubes, often in groups of adjacent nuclei. Quantification re-
vealed that about 5% of myonuclei from differentiated cultures
stained DUX4+, whereas in the myoblast cultures, DUX4 protein
was present in about 1.5% of nuclei (Figure 4F). This result is not
necessarily suggestive of greater expression in differentiated
cultures: myotubes are syncitia, therefore active DUX4 tran-
scription in one nucleus can lead to uptake and positive staining
of nuclear proteins in nearby myonuclei (Block et al., 2013; Tas-
sin et al., 2013), so at the same frequency of expression, myo-
tubes are predicted to have greater numbers of positive nuclei1488 Cell Reports 8, 1484–1496, September 11, 2014 ª2014 The Authan myoblasts. Indeed, a careful comparison of two indepen-
dent myoblast and myotube cultures revealed very similar levels
of expression at the RNA level before versus after differentiation
(Figure 4G), although it is important to point out that these results
are nonquantitative. The lack of detectable protein in most
nuclei by immunostaining, as well as the lack of detectable
protein in FAPs, may indicate the sensitivity of the assay is
limiting. Indeed, between laboratories, the immunohistochem-
ical method has produced widely varying estimates of fre-
quencies of nuclei positive for DUX4 in FSHD (and control)
myoblasts (Jones et al., 2012; Snider et al., 2010).thors
(legend on next page)
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Induced DUX4 Expression Is Selectively Deleterious to
Myogenic Progenitors
The studies described above were undertaken in the absence of
dox; therefore, phenotypes are due to extremely low-level, leaky
expression. To evaluate the utility of dox-mediated DUX4
expression, we tested whether the inducible locus was func-
tional by treating myoblast and FAP cultures with a high dose
of dox (500 ng/ml) for 24 hr. This confirmed that the inducible
system was indeed working as expected: DUX4 protein was ex-
pressed in response to dox (Figure 5A). We then subjected
ex vivo cultures of myoblasts and FAPs to various lower concen-
trations of dox. In bothmyoblasts and FAPs, expression of DUX4
was deleterious; however, growth inhibition was more severe in
myoblasts (Figures 5B and 5C).
Low, nontoxic levels of DUX4 expression were shown to inter-
fere with the differentiation of C2C12 myoblasts (Bosnakovski
et al., 2008a). To determine DUX4 effects on primary cells, we
induced differentiation of myoblasts (into myotubes) and FAPs
(into adipocytes) in the presence of low levels of dox (50 ng/ml).
Myotube formation was clearly impaired by DUX4 expression,
whereas adipocyte differentiation was unaffected (Figure 5D).
DUX4 Impairs Myogenic Regeneration In Vivo
To test the effect of DUX4 expression during myogenic regener-
ation in vivo, we transplanted 1,800 FACS-isolated satellite cells
from hind limb muscle of iDUX4(2.7) mice into preinjured, irradi-
ated tibialis anterior muscles of NSG-mdx4Cv mice (Arpke et al.,
2013). The recipients lack dystrophin; thus, the amount of donor
muscle tissue produced by the transplanted cells can be quan-
tified by immunostaining for dystrophin. We found that treatment
of mice with 5 mg/kg doxycycline severely impaired the ability of
donor satellite cells to produce new muscle (Figures 6A and 6B).
This indicates that DUX4 expression is deleterious to muscle
regeneration in vivo.
DISCUSSION
FSHD is one of the most enigmatic of the muscular dystrophies,
and despite many efforts, there is no genetic model that displays
any phenotype for this disease. In humans, reduction in repeat
number (or second-site mutation in rare noncontraction cases;
i.e., FSHD2; Lemmers et al., 2012), clearly leads to an epigenetic
alteration at D4Z4 (van Overveld et al., 2003) that impairs repeat-
induced silencing allowing D4Z4 transcription (Block et al., 2013;Figure 4. Methylation and DUX4 Expression in Primary Cells
(A)Methylation of the iDUX4(2.7) transgene in various tissues and primarymuscle c
boxes indicate unmethylated cytosines of CpG dinucleotides, and red boxes ind
(B) Methylation of the transgene inmale and female peripheral blood. Onemale ag
Methylated sequences in females were greatly overrepresented compared to the
(C) RT-PCR detection of the DUX4 transcript in proliferating myoblasts and FAPs
(D) Growth rate of iDUX4(2.7) myoblasts and FAPs compared to cells from WT li
difference was seen in FAP growth rate. One experiment of three similar replicat
(E) Immunofluorescent detection of DUX4 protein in myoblasts and myotubes. S
(MHC) (in green).
(F) Quantification of DUX4+ nuclei, expressed as average percentage and SD of to
is shown.
(G) Comparison of levels of DUX4 expression by RT-PCR in myoblasts versus m
See also Figure S1.
1490 Cell Reports 8, 1484–1496, September 11, 2014 ª2014 The AuJones et al., 2012; Snider et al., 2009). Although a recently
described mouse bearing randomly integrated tandem D4Z4 re-
peats from an FSHD allele showed some expression of D4Z4
transcript (Krom et al., 2013), this animal did not present pro-
found pathologies. With the recognition that DUX4 has potent
myogenesis-relevant phenotypes even at very low levels of
expression in C2C12 cells (Bosnakovski et al., 2008a), we sought
to generate an animal model based on low-level regulated and
systemic expression of DUX4. Systemic expression is relevant
because D4Z4 misexpression in FSHD has not been shown to
be restricted to myoblasts or muscle fibers. Indeed, the pres-
ence of nonmuscle phenotypes such as retinal vascular pathol-
ogy (Fitzsimons et al., 1987; Gieron et al., 1985; Small, 1968) and
sensorineural hearing loss (Brouwer et al., 1991; Lutz et al., 2013)
in FSHD patients, the syndrome of phenotypes associated with
very severe infantile FSHD cases with extremely short D4Z4 ar-
rays (Chen et al., 2013), together with the demonstration of
epigenetic changes also in the blood cells of FSHD patients
(Hartweck et al., 2013; van Overveld et al., 2003), suggests
that misexpression is not restricted to muscle and might be a
global feature. Remarkably, in our allele, we found that low-level
leaky and variable expression led to several severe phenotypes,
making the iDUX4(2.7) mouse an animal model in which FSHD
allele-specific DNA has been integrated into the genome and
caused a serious pathology.
This pathology is dominant, like FSHD, but dramatically more
potent, resulting in male-specific lethality. In humans, the D4Z4
repeats are embedded in subtelomeric heterochromatin and
subject to repeat-induced silencing, whereas in this mouse
model, the transgene has been inserted into euchromatin and
is present in only a single copy. Thus, D4Z4 has lost both the op-
portunity for repeat-induced silencing as well as its normal het-
erochromatic genomic environment, both changes that would
be predicted to render the transgene more potent than 4q35-
linked FSHD alleles (Figure 7). This may explain why the DUX4
transgene has a much stronger dominant-lethal phenotype in
this mouse model than in human patients with FSHD. It may
also explain the presence of phenotypes in unexpected tissues,
for example, skin; however, vector-specific sequences may also
contribute to tissue-specific aspects of the leakiness, for
example, the minimal promoter might be leaky in skin cells,
whereas the endogenous human D4Z4 might not show skin
expression. For obvious reasons, outside of muscle biopsies, a
careful analysis of tissues in which DUX4 expression can beells. Bisulfite-treated DNAwas amplified by PCR, cloned, and sequenced. Blue
icate methylated cytosines along the PCR product.
ed 6 weeks and three independent females aged 6, 9, and 36weeks are shown.
1:1 ratio predicted by X inactivation for a heterozygous female (p = 0.0).
.
ttermate controls. Myoblasts displayed a significant growth disadvantage. No
es is shown.
ections are also stained with DAPI (blue) and antibody to myosin heavy chain
tal per microscopic field, over 19 separate fields. One of three similar replicates
yotubes.
thors
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Figure 5. Effects of Induced DUX4 Expression
(A)Western blot for DUX4 expression in proliferatingmyoblasts and FAPs exposed to a high dose (500 ng/ml) of dox. One representative blot of three independent
experiments is shown.
(B) Dox dose-response growth curves for myoblasts (left) and FAPs (right) exposed to very low doses of dox to induce DUX4 expression. Myoblasts displayed a
more severe growth inhibition and greater sensitivity to dox.
(C) Cellular morphology of proliferating myoblast (left) and FAP (right) cultures exposed to a high dose (500 ng/ml) of dox.
(D) Myoblasts and FAPs exposed to a low dose (50 ng/ml) of dox and cultured under myogenic or adipogenic differentiation conditions, respectively. Myotubes
(left) were stained for myosin heavy chain; adipocytes (right) were stained with Oil Red O. Note that low-dose induction of DUX4 inhibits myogenic, but not
adipogenic, differentiation.
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AB
Figure 6. DUX4 Expression Impairs
Myogenic Regeneration In Vivo
(A) Representative examples of TA muscles
1 month after transplantation of 1,800 iDUX4(2.7)
satellite cells in the presence or absence of daily
doxycycline injection (either 1mg/kg or 5mg/kg) to
induce DUX4 or control carrier (PBS) injection. The
overall muscle architecture is indicated by laminin
staining (green). Donor cell contribution to new fi-
bers is evaluated by counting Dystrophin+ (red)
fibers. Doxycycline treatment impaired contribu-
tion to myofiber regeneration in a dose-dependent
manner.
(B) Quantification of myofiber engraftment. For
each group, n = 6. Bars indicate SD.detected in humans has never been reported. With regard to pa-
thologies in testes, this was somewhat surprising as DUX4 has
been reported in human testes (Snider et al., 2010). The closest
mouse homolog, Dux, was not reported expressed in testes
(Clapp et al., 2007); however, a different double homeobox pro-
tein, Duxbl, which lacks the C-terminal sequence conserved be-
tween DUX4 and mouse Dux (Leidenroth and Hewitt, 2010)
important for toxicity (Bosnakovski et al., 2008b), is expressed
in testes (Wu et al., 2010). The presence of testis pathology in
iDUX4(2.7) mice suggests that, if DUX4 has a specific function
in testes, then this is probably a human-specific activity.
It is notable that the retinae of the iDUX4(2.7) animals demon-
strate pathological retinal vascular changes like those seen in
FSHD patients. It is not yet understood how the D4Z4 contraction
leads to these changes in humans; however, it has been pro-
posed that the muscle pathology and the retinal pathology might
both be attributed to an endothelial defect (Osborne et al., 2007).
The iDUX4(2.7) mice also resemble FSHD patients in terms of
DUX4 expression at the RNA and protein level: a spliced mRNA
encoding DUX4 can be detected at very low levels in many tis-
sues, but the DUX4 protein itself cannot or is expressed in so
few cells as to be difficult to distinguish from background in im-
munostaining experiments. Within the short lifespan of the rare
live-born affectedmales, amuscular dystrophy does not develop.
Whether or not muscular dystrophy (MD) would develop if the an-
imals were to survive beyond 4–6 weeks, the absence of dystro-
phy is consistent with the lack of muscle pathology in young
FSHD patients. The literature is inconsistent on fiber type
changes in FSHD (Lin and Nonaka, 1991; Olsen et al., 2005),
but neither do the mice show any signs of fiber type switching.
Unlike Duchenne MD, in which pathological cycles of damage
and regeneration are present from birth, FSHD muscles appear
histologically normal prior to onset of the disease. The female
mice do survive, but neither did they show signs of muscular dys-
trophy. However, in heterozygous carrier females, the DUX4
transgene appears to be predominantly on the inactive X chromo-1492 Cell Reports 8, 1484–1496, September 11, 2014 ª2014 The Authorssome, as it is heavily methylated. As X
inactivation is random, this is best ex-
plained by positive selection for cells that
silence the DUX4-bearing X chromosome.
To evaluate more directly the effect of
DUX4 on primary muscle progenitors, westudied myogenic and fibroadipogenic progenitors from
iDUX4(2.7) males. DUX4 mRNA was indeed expressed at low
levels in both myoblasts and FAPs and was associated with a
reduction in proliferative potential, more significantly to myo-
blasts. Doxycycline induction at high doses was clearly inhibitory
to both myoblasts and FAPs, whereas low levels inhibited differ-
entiation of myoblasts into multinucleated myotubes, but not of
FAPs into adipocytes. The DUX4 effects on primary muscle pro-
genitors raise the question of whether a defect in regeneration
contributes to muscle pathology in FSHD. Accordingly, when
iDUX4(2.7) satellite cells were transplanted and recipients treated
with a relatively low dose of doxycycline, their ability to generate
new muscle tissue was severely impaired. The data do not
formally differentiate between effects on progenitors versus
newly formed myofibers—certainly when very high levels of
DUX4 were delivered directly to mouse muscles tissues by ad-
eno-associated virus, there was extensive degeneration (Wallace
et al., 2011). However, the data are consistent with the notion that
DUX4 could impair muscle regeneration in FSHD. Most impor-
tantly, they represent a quantifiable assay that could be used to
study the activity of pharmacological inhibitors of DUX4 in vivo.
This is an animal model in which FSHD allele-specific DNA has
been integrated into the genome and has generated a patholog-
ical phenotype. It clearly demonstrates that even low-level
expression from the terminal D4Z4 repeat is highly deleterious;
is consistent with a model for FSHD in which muscle wasting is
a consequence, at least in part, of impaired regeneration; and
presents opportunities for testing activity of anti-DUX4 therapeu-
tics in vivo.
EXPERIMENTAL PROCEDURES
Cloning of Targeting Construct and Generation of iDUX4(2.7) Mice
The genomic DNA encoding DUX4 from the terminal repeat together with
downstream sequence (2.7 kb total) was obtained from pClneo-DUX4 (Ga-
brie¨ls et al., 1999) and subcloned into XhoI/NotI cloning sites of p2Lox, gener-
ating p2lox-DUX4(2.7). iDUX4(2.7)-inducible mouse embryonic stem cell
Figure 7. The iDUX4(2.7) Allele versus Human D4Z4 Alleles
D4Z4 is indicated by a triangle. Methylation state is indicated at six repre-
sentative sites for each array, with a red ball indicating methylation and an
open circle indicating lack of methylation. In humans, when D4Z4 is present in
a large tandem array within subtelomeric heterochromatin at 4q, a repeat-
induced silencing mechanism leads to heterochromatinization of the array
(indicated by compaction of the triangles and their respective methylation
marks) and hypermethylation of DNA (indicated by red circles), which effec-
tively silences the locus.When the array number is reduced in an FSHD allele, a
loss of repeat-induced silencing leads to an opening up of chromatin (more
space between the triangles) and a relative demethylation, leading to some
transcription of DUX4. In the iDUX4(2.7) mouse, the single copy (which is
not subject to repeat-induced silencing) and location within euchromatin
results in even greater opening, a complete absence of methylation, and
greater transcription in additional tissues, leading to a more severe, lethal,
phenotype.(mESC) lines were generated by inducible cassette exchange recombination
using an improved version of the A2Lox.cre mESC lines (ZX1 cells, which
contain the second generation tetracycline-response element) as previously
described (Iacovino et al., 2011). iDUX4(2.7) mice were derived at the Univer-
sity of Texas Southwestern Transgenic Core Facility by blastocyst injection of
iDUX4(2.7) ESCs. Mice were maintained under the guidance of the University
of Texas Southwestern and University of Minnesota Institutional Animal Care
and Use Committees.
RNA Isolation and RT-PCR for DUX4
RNA was isolated from fresh tissue samples dissected from iDUX4(2.7) and
control male mice. Tissues were homogenized in Trizol (Invitrogen), and
RNA was precipitated according to the manufacturer’s directions. The high
GC content of DUX4 required the use of a high-temperature reverse transcrip-
tase. We treated 1.5 mg RNA for 30 min with DNase (Promega), and the cDNA
was produced using Thermoscript polymerase and oligo dT primer according
to the manufacturer’s directions. DUX4 transcript was analyzed by semiquan-
titative PCR using Takara LA Taq with GC rich buffer II and the following con-
ditions: primers PLH394F: GCTGGAAGCACCCCTCAGCGAGGAA and
PLH395R: TCCAGGTTTGCCTAGACAGCGTC; denaturation at 94C for 15 s;
annealing at 57C for 15 s; and elongation at 72C for 30 s. RNA experiments
were performed with at least three biological replicates, and representative re-
sults are shown.
Statistical Analyses
GraphPad Prism was used with all samples to compute means, SDs, and p
values by t test.
Histological Analysis
Skin samples were harvested from iDUX4(2.7) and control littermates
(three of each), fixed in 10% neutral buffered formalin containing 0.1 M
CaCl2 for 2 days, and embedded in paraffin. Four-micrometer sections
were evaluated by hematoxylin and eosin (H&E) staining. Testes (from six
iDUX4(2.7) and three littermate control males) were prepared in Bouin’s fixa-
tive and processed for sectioning and H&E staining as described (Hao et al.,
2008).Cell ReSkeletal Muscle Contractile and Histological Analyses
EDL and soleus muscles were carefully dissected andmaximal isometric force
generating capacities measured. For histology, muscles were embedded in
OCT. Ten-micrometer sections were evaluated by H&E staining, NADH reac-
tivity, and myosin heavy chain expression as described (Greising et al., 2012).
Retinal Vascular Imaging
Retinae were isolated immediately following euthanasia, fixed in Zamboni’s
fixative for 24 hr, washed, and stored in 20% sucrose + 0.5% sodium azide
at 4C. Whole retinae were incubated with 5% donkey serum overnight and
immunostained with rat anti-CD31/PECAM-1 (Santa Cruz Biotechnology) at
1:200 dilution for 12 hr at room temperature, followed by 6 hr of washing
and incubation with Cy2-conjugated secondary antibody (Jackson Immunor-
esearch) at 1:500 dilution for 12 hr at room temperature. Retina flat mounts
were imaged using 2-micron-thick z stacks on a Fluoview FV1000
BX2 Upright Laser scanning confocal microscope (Olympus Corporation)
with a 203 or 403 oil objective lens. Images were analyzed using Adobe Pho-
toshop and Reindeer Games software to quantify different measures of retinal
vasculature, as described previously (Gupta et al., 2002).
Isolation and Differentiation of Myoblasts and FAPs from Muscle
Preparation of muscle samples was performed as described (Arpke et al.,
2013). We then plated 106 total mononuclear cells in a T25 flask in F-10/
Ham’s (Hyclone) medium containing 20% fetal bovine serum (HyClone),
50 ng/ml human basic fibroblast growth factor (Peprotech), 1%penicillin/strep-
tomycin (Gibco), and 1% Glutamax (Gibco) and cultured at 37C under
reduced oxygen conditions (5% O2, 5% CO2, and 90% N2). After 4 days, pri-
mary cells were disassociated with 0.05% trypsin (Invitrogen) and resus-
pended in FACS staining medium. To isolate myoblast and FAP fractions, cells
were stained with PDGFRa conjugated with phycoerythrin (e-Biosciences;
clone: APA5) and a7 integrin APC. Cells were sorted into a PDGFRa single-
positive (FAP fraction) and an a7 integrin single-positive (myoblast) fraction
and recultured in the same medium. Myoblasts were differentiated in 20%
knockout serum replacer (Invitrogen) as described in Block et al. (2013).
FAPs were differentiated in dexamethasone (STEMCELL Technologies) as
described in Lemos et al. (2012). To detect DUX4 by western blot or by immu-
nostaining in primary myoblasts and myotubes, E5-5 DUX4 antibody (Abcam)
was used as described (Geng et al., 2011). Myosin heavy chain staining used
the MF20 antibody (Developmental Studies Hybridoma Bank).
Methylation Analysis
Bisulfite sequencing was generally performed as described in Hartweck et al.
(2013). Tissues from six malemice at 6 weeks of age and three females aged 6,
9, and 36 weeks were analyzed. DNA was extracted using the PureLink
Genomic DNA Mini Kit (Invitrogen). Five hundred nanograms DNA was con-
verted with the EZ DNA Methylation direct kit (Zymo Research) and eluted in
20 ml. Converted DNA (2 ml) was amplified with primer sets: DR3F: GTA
GAGGGGATTTTTTAATTTGTTT and DR3R: CAAACACCCCTTAACCCTAC
using Takara ExTaq (QIAGEN) according to manufacturers’ instructions with
cycling parameters: denature: 94C 60 s, cycle: 94C 10 s, 60C 15 s, 72C
20 s, for 30 cycles; final extension at 72C 5 min. PCR products were purified
from 2% agarose gels with Wizard SVgel and PCR Purification system (Prom-
ega) cloned with the TOPO T/A cloning kit (Invitrogen) and clones with 223 bp
inserts, sequenced. To determine if frequency of methylated X chromosomes
with the iDux4(2.7) transgene was greater than the expected frequency (50%),
we pooled the female data and used the exact binomial test. This specific PCR
represents methylated and unmethylated chromosomes equally (Hartweck
et al., 2013).
Transplantation of Satellite Cells and Fiber Engraftment
Pax7-ZsGreen male mice, in which satellite cells are marked with green fluo-
rescence (Bosnakovski et al., 2008c), were crossed to iDUX4(2.7) females to
generate iDUX4(2.7); Pax7-ZsGreen males from which satellite cells were iso-
lated by flow cytometry as described in Arpke et al. (2013). In an independent
replicate that gave similar results, satellite cells were also isolated based on
surface markers as described previously (Chan et al., 2013). First dead cells
were gated out with propidium iodide, and then blood and endothelial lineagesports 8, 1484–1496, September 11, 2014 ª2014 The Authors 1493
were gated out using anti-CD31 (eBioscience; clone 390) and rat anti-CD45
(eBioscience; clone RA3-6B2) antibodies conjugated to phycoerythrin-Cy7.
Finally, satellite cells were sorted by being double positive for CD106 (eBio-
science; biotinylated primary VCAM-1 antibody; clone 429; followed by strep-
tavidin secondary antibody conjugated with phycoerythrin) and a-7 integrin
conjugated with allophycocyanin (AbLab; clone R2F2).
Transplantation was according to Arpke et al. (2013). Briefly, 2 days prior to
transplantation of cells, 4-month-old NSG-mdx4Cv mice were anesthetized
with ketamine and xylazine and both hind limbs were subjected to a 1,200
cGy dose of irradiation using an X-RAD 320 Biological Irradiator (Precision
X-Ray). On the day of transplantation, 1,800 sorted satellite cells were resus-
pended in 1.2% BaCl2 (RICCA Chemical Company) and injected into tibialis
anterior (TA) muscles of NSG-mdx4Cv mice. Every day posttransplantation,
we injected mice with PBS or doxycycline at 1 mg/kg or 5 mg/kg. Four weeks
after transplantation, six TAs of each group were harvested, sectioned, and
immunostained with a mouse monoclonal antibody to laminin (Sigma-Aldrich)
and rabbit polyclonal antibody to dystrophin (Abcam) antibodies followed by
goat anti-mouse immunoglobulin G (IgG) conjugated with Alexa 488 and
goat anti-rabbit IgG conjugated with Alexa Fluor 555 (Life Science Technolo-
gies). Images were acquired on a Zeiss Axio Imager M1 Upright microscope
with AxioCam HRc camera, and the number of donor-derived fibers (dystro-
phin+) was determined.
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